Veru Inc. (NASDAQ:VERU - Get Free Report) passed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $0.81 and traded as low as $0.64. Veru shares last traded at $0.68, with a volume of 1,431,955 shares changing hands.
Wall Street Analyst Weigh In
Several research analysts have recently commented on VERU shares. HC Wainwright reissued a "buy" rating and issued a $3.00 price target on shares of Veru in a research report on Friday, December 20th. Oppenheimer reissued an "outperform" rating and set a $5.00 price target on shares of Veru in a research report on Tuesday, November 5th.
Get Our Latest Report on Veru
Veru Stock Down 1.3 %
The company has a market capitalization of $98.93 million, a price-to-earnings ratio of -1.41 and a beta of -0.50. The business's 50-day moving average is $0.72 and its 200-day moving average is $0.81.
Veru (NASDAQ:VERU - Get Free Report) last posted its earnings results on Monday, December 16th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.01. Veru had a negative net margin of 376.38% and a negative return on equity of 115.99%. As a group, analysts expect that Veru Inc. will post -0.3 EPS for the current year.
Hedge Funds Weigh In On Veru
A number of hedge funds have recently made changes to their positions in the company. Gladstone Institutional Advisory LLC increased its holdings in shares of Veru by 34.2% in the third quarter. Gladstone Institutional Advisory LLC now owns 56,876 shares of the company's stock valued at $44,000 after purchasing an additional 14,500 shares during the last quarter. Blair William & Co. IL boosted its position in shares of Veru by 6.1% during the 2nd quarter. Blair William & Co. IL now owns 350,000 shares of the company's stock valued at $294,000 after acquiring an additional 20,000 shares during the last quarter. Zacks Investment Management purchased a new stake in shares of Veru in the third quarter valued at about $25,000. SG Americas Securities LLC increased its position in Veru by 185.9% during the third quarter. SG Americas Securities LLC now owns 66,128 shares of the company's stock worth $51,000 after purchasing an additional 42,997 shares during the last quarter. Finally, Jane Street Group LLC increased its position in Veru by 142.8% during the third quarter. Jane Street Group LLC now owns 96,454 shares of the company's stock worth $74,000 after purchasing an additional 56,736 shares during the last quarter. Institutional investors and hedge funds own 47.16% of the company's stock.
About Veru
(
Get Free Report)
Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.
Featured Articles
Before you consider Veru, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Veru wasn't on the list.
While Veru currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
